4See Ventures

What 4See Ventures does

4See Ventures is a Swiss venture capital firm founded in 2019 by Daniel Bertholet and headquartered in the Geneva area (Chêne-Bougeries). The firm invests in early-stage Swiss startups across climatech, sustainability, and healthcare, with current thematic emphasis on climatech. Initial investments range from CHF 400,000 to CHF 1 million per company, with potential lifetime commitments of up to CHF 10 million, deployed from the firm's own capital alongside institutional co-investors. The team is small (1–10 employees), comprising founder and managing partner Daniel Bertholet and independent board member Robert-Philippe Bloch.

The firm's active portfolio of approximately nine companies spans diverse sectors: robotic surgery (Distalmotion's Dexter platform, FDA-authorized in October 2024), RNA-guided therapeutics (HAYA Therapeutics, which raised a $65M Series A in 2025), nuclear waste transmutation (Transmutex), AI-driven precision neuroscience (Stalicla's DEPI platform for autism spectrum disorder), sustainable building insulation (FenX, an ETH Zurich spin-off), data and satellite cybersecurity (Cysec), late-stage AML biotech (Priothera), and a youth community platform (Goodwall). The firm does not charge portfolio companies for services; returns are realized through equity stakes via future funding rounds, acquisitions, or IPOs. Marketing is conducted primarily through the firm's website and founder's professional network.

Name

4See Ventures

Legal name

4See Ventures SA

Website

https://4seeventures.ch

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

4See Ventures is a Swiss venture capital firm founded in 2019 by Daniel Bertholet that invests its own capital in early-stage Swiss startups in climatech, sustainability, and healthcare, with initial checks of CHF 400k–1m and lifetime commitments up to CHF 10m per company.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Portfolio Management and Investment Advice (52394), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

Keywords

• Venture capital investing
• Early stage startups
• Climatech investments
• Healthcare venture capital
• Seed series A funding

Headquarters

HQ city

Secheron

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Equity Investment Returns: 4See Ventures generates returns through equity investments in portfolio companies. Returns are realized through funding rounds where the firm's stake may be diluted or through exits via acquisitions or IPOs of portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

4See Ventures is a Swiss venture capital firm that invests equity capital in early-stage startups from seed through Series A and B. Initial investments range from CHF 400k to CHF 1m per company, with total commitments up to CHF 10m over the investment lifetime, accompanied by hands-on strategic support in corporate strategy, financing strategy, and governance. The firm currently focuses on Swiss startups in climatech and sustainability, with a historical emphasis on healthcare.

Product overview

4See Ventures is a Swiss venture capital firm (not a product/technology company) that invests in entrepreneurs across climatech, sustainability, and healthcare sectors. The firm primarily invests in Swiss early-stage startups from seed through Series A/B stages. Their portfolio includes eight companies: Distalmotion (Dexter® surgical robot for soft tissue surgery), HAYA Therapeutics (RNA-guided therapeutics for heart failure and cancer), Transmutex (nuclear waste transmutation technology), STALICLA (AI-driven precision neuro medicine platform DEPI for autism and substance use disorders), FenX (sustainable building insulation), Cysec (satellite and data cybersecurity), Priothera (AML cancer treatment), and Goodwall (student/professional networking platform).

Differentiator

Problem solved

Functional benefit

Products and services

• 4See Ventures Investment Services

Quantifiable outcome

• Invested in companies including Distalmotion, Haya Therapeutics, Transmutex, Goodwall, Stalicla, FenX, NetGuardians and Cysec

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Scale indicators3 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Verve Ventures: Verve Ventures is one of Switzerland's most active early-stage investors, deploying capital across a broad range of sectors from a Swiss base. Directly comparable to 4See Ventures given shared Swiss early-stage mandate and similar ticket sizes, though Verve operates at significantly larger scale with a much broader sector mandate.
• btov Partners: btov Partners is a European venture firm with a strong Swiss presence, investing across deep tech, digital, and industrialtech from seed through Series B. Comparable to 4See given its early-stage focus and pan-European footprint, though btov has broader sector coverage and deeper institutional backing.
• Wingman Ventures: Wingman Ventures is a Swiss early-stage fund focused on technology-enabled startups, primarily in B2B software and deep tech. Directly comparable to 4See given the Swiss base and early-stage orientation, though Wingman focuses more on enterprise software while 4See leans climatech and healthcare.
• Redstone VC: Redstone is a Berlin-based but DACH-focused early-stage venture firm investing in climate, fintech, and digital health. Comparable to 4See via the early-stage climate/health orientation, though Redstone operates with a slightly larger team and broader DACH geographic footprint.
• Endeavour Vision: Endeavour Vision is a specialist medtech and digital health investor in Europe and the US where Daniel Bertholet previously worked. Directly comparable to 4See through the healthcare/life sciences focus and similar stage, though Endeavour operates at larger fund size and broader geographic footprint.
• Reference Capital: Reference Capital is a Swiss investment firm where Daniel Bertholet began his venture career in 2003. Comparable given the Swiss base and growth equity orientation, though Reference operates more as a multi-strategy investment vehicle with broader asset class exposure.

Broad incumbents

• Swisscom Ventures: Swisscom Ventures is the corporate venture arm of Swisscom, investing in early to growth-stage ICT, digital media, and adjacent technology companies. Comparable as a major Swiss-based early-stage investor, though it operates with corporate strategic objectives and much larger capital base.
• Emerald Technology Ventures: Emerald Technology Ventures is a Zurich-based global investor in clean technology, energy, and sustainable innovation. Comparable to 4See's sustainability and climatech portfolio theme, though Emerald operates at much larger scale and with global reach across later stages.

Regional players

• Alpana Ventures: Alpana Ventures is a Geneva-based early-stage firm investing in digital health, enterprise SaaS, and fintech across Switzerland. Comparable to 4See given the shared Swiss/Geneve base and early-stage orientation, though Alpana focuses on software-led businesses rather than climatech and biotech.

Emerging players

• Climate Capital Coalition: Climate Capital Coalition is an emerging climate-focused investment platform backing early-stage European climate-tech ventures. Comparable to 4See through the climatech focus, though it operates more as a coalition/platform model rather than a traditional single-fund GP.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/4seeventures

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4See Ventures